Skip to main content Accessibility help
  • Print publication year: 2011
  • Online publication date: April 2011

Chapter 49 - Renal protection and pharmacology

Related content

Powered by UNSILO


1. Levens NR, Peach MJ, Carey RM. Role of the intrarenal reninangiotensin system in the control of renal function. Circ Res 1981; 48: 157–67.
2. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 1): S1–266.
3. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003; 139: 137–47.
4. Stevens LA, Coresh J, Greene T, Levey AS. Assessing kidney function –measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473–83.
5. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure – definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care; 8: R204–12.
6. Uchino S, Bellomo R, Goldsmith D, Bates S, Ronco C. An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. Crit Care Med 2006; 34: 1913–17.
7. Mehta RL, Kellum JA, Shah SV, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 11: R31.
8. Bagshaw SM, George C, Bellomo R. A comparison of the RIFLE and AKIN criteria for acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008; 23: 1569–74.
9. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet 2005; 365: 417–30.
10. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004; 114: 5–14.
11. Krishnan M. Preoperative care of patients with kidney disease. Am Fam Physician 2002; 66: 1471–6, 1379.
12. Carmichael P, Carmichael AR. Acute renal failure in the surgical setting. ANZ J Surg 2003; 73: 144–53.
13. US Renal Data System. USRDS 2007 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States. Bethesda, MD: NIH, National Institute of Diabetes and Digestive and Kidney Diseases, 2007.
14. Hillis GS, Croal BL, Buchan KG, et al. Renal function and outcome from coronary artery bypass grafting: impact on mortality after a 2.3-year follow-up. Circulation 2006; 113: 1056–62.
15. Ympa YP, Sakr Y, Reinhart K, Vincent JL. Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med 2005; 118: 827–32.
16. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365–70.
17. Moran SM, Myers BD. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int 1985; 27: 928–37.
18. Hewitt SM, Dear J, Star RA. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 2004; 15: 1677–89.
19. Jones DR, Lee HT. Protecting the kidney during critical illness. Curr Opin Anaesthesiol 2007; 20: 106–12.
20. Sladen RN, Landry D. Renal blood flow regulation, autoregulation, and vasomotor nephropathy. Anesthesiol Clin North America 2000; 18: 791–807.
21. Ballerman BJ, Zeidel ML, Gunning ME, Brenner BM. Vasoactive peptides and the kidney. In: Brenner BM, Rector FCJ, eds., The Kidney, 4th edn. Philadelphia, PA: WB Saunders, 1991: 510–83.
22. Gerber JG, Olsen RD, Nies AS. Interrelationship between prostaglandins and renin release. Kidney Int 1981; 19: 816–21.
23. Garella S, Matarese RA. Renal effects of prostaglandins and clinical adverse effects of nonsteroidal anti-inflammatory agents. Medicine 1984; 63: 165–81.
24. Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 2008; 21: 733–41.
25. Holtbäck U, Kruse MS, Brismar H, Aperia A. Intrarenal dopamine coordinates the effect of antinatriuretic and natriuretic factors. Acta Physiol Scand 2000; 168: 215–18.
26. Stanton BA, Koeppen BM. Elements of renal function. In: Berne RM, Levy MN, eds., Physiology, 3rd edn. St Louis, MO: Mosby Year-Book, 1993: 719–53.
27. Schrier RW. Effects of the adrenergic nervous system and catecholamines on systemic and renal hemodynamics, sodium and water excretion and renin secretion. Kidney Int 1974; 6: 291–306.
28. Maddox DA, Brenner BM. Glomerular ultrafiltration. In: Brenner BM, Rector FCJ, eds., The Kidney, 4th edn. Philadelphia, PA: WB Saunders, 1992: 215–31.
29. Edwards RM, Rizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonist. Am J Physiol 1989; 256: F526–34.
30. Shipley RE, Study RS. Changes in renal blood flow, extraction of inulin, glomerular filtration rate, tissue pressure and urine flow with acute alterations of renal artery pressure. Am J Physiol 1951; 167: 676–88.
31. Desjars PH, Pinaud M, Bugnon D, et al. Norepinephrine has no deleterious renal effects in human septic shock. Crit Care Med 1989; 17: 426–9.
32. Kelleher SP, Robinette JB, Miller F, Conger JD. Effect of hemorrhagic reduction in blood pressure on recovery from acute renal failure. Kidney Int 1987; 31: 725–30.
33. Mackay JH, Feerick AE, Woodson LC, et al. Increasing organ blood flow during cardiopulmonary bypass in pigs: comparison of dopamine and perfusion pressure. Crit Care Med 1995; 23: 1090–8.
34. Brezis M, Rosen S. Hypoxia of the renal medulla: its implications for disease. N Engl J Med 1995; 332: 647–55.
35. Puschett JB. Pharmacological classification and renal actions of diuretics. Cardiology 1994; 84: 4–13.
36. Behnia R, Koushanpoor E, Brunner EA. Effects of hyperosmotic mannitol infusion on hemodynamics of dog kidney. Anesth Analg 1996; 82: 902–8.
37. Johnson PA, Barnard DB, Perrin NS, Levinsky NG. Prostaglandins mediate the vasodilatory effect of mannitol in the hypoperfused rat kidney. J Clin Invest 1981; 68: 127–33.
38. Blantz CA. Effect of mannitol on glomerular ultrafiltration in the hydropenic rat. J Clin Invest 1974; 54: 1135–43.
39. Lang F. Osmotic diuresis. Renal Physiol 1987; 10: 160–73.
40. Schrier RW, Arnold PE, Gordon JA, Burke TJ. Protection of mitochondrial function by mannitol in ischemic acute renal failure. Am J Physiol 1984; 247: F365–9.
41. Zager RA, Foerder C, Bredl C. The influence of mannitol on myoglobinuric acute renal failure: functional, biochemical, and morphological assessments. J Am Soc Nephrol 1991; 2: 848–55.
42. Mason J. The pathophysiology of ischemic acute renal failure: a new hypothesis about the initiation phase. Ren Physiol 1986; 9: 129–47.
43. Burg M, Stoner L. Renal tubular chloride transport and the mode of action of some diuretics. Annu Rev Physiol 1976; 38: 37–45.
44. Kaissling B, Stanton BA. Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. Am J Physiol 1985; 248: F374–81.
45. Sica DA, Gehr TW. Diuretic combinations in refractory oedema states: pharmacokinetic–pharmacodynamic relationships. Clin Pharmacokinet 1996; 30: 229–49.
46. Chambrey R, Achard JM, St John PL, et al. Evidence for an amiloride-insensitive Na/H exchanger in rat renal cortical tubules. Am J Physiol 1997; 273: C1064–74.
47. Zeng C, Zhang M, Asico LD, Eisner GM, Jose PA. The dopaminergic system in hypertension. Clin Sci (Lond) 2007; 112: 583–97.
48. Roberts I, Alderson P, Bunn F, et al. Colloids versus crystalloids for fluid resuscitation in critically ill patients.Cochrane Database Syst Rev 2004 (4): CD000567.
49. O'Malley CM, Frumento RJ, Hardy MA, et al. A randomized, double-blind comparison of lactated Ringer's solution and 0.9% NaCl during renal transplantation. Anesth Analg 2005; 100: 1518–24.
50. Balogh Z, McKinley BA, Cocanour CS, et al. Supranormal trauma resuscitation causes more cases of abdominal compartment syndrome. Arch Surg 2003; 138: 637–42; discussion 42–3.
51. Schortgen F, Lacherade JC, Bruneel F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001; 357: 911–16.
52. Sakr Y, Payen D, Reinhart K, et al. Effects of hydroxyethyl starch administration on renal function in critically ill patients. Br J Anaesth 2007; 98: 216–24.
53. Mockel M, Scheinert D, Potapov EV, et al. Continuous measurements of renal perfusion in pigs by means of intravascular Doppler. Kidney Int 2001; 59: 1439–47.
54. Bourgoin A, Leone M, Delmas A, et al. Increasing mean arterial pressure in patients with septic shock: effects on oxygen variables and renal function. Crit Care Med 2005; 33: 780–6.
55. Deruddre S, Cheisson G, Mazoit JX, et al. Renal arterial resistance in septic shock: effects of increasing mean arterial pressure with norepinephrine on the renal resistive index assessed with Doppler ultrasonography. Intensive Care Med 2007; 33: 1557–62.
56. Hara T, Fukusaki M, Nakamura T, Sumikawa K. Renal function in patients during and after hypotensive anesthesia with sevoflurane. J Clin Anesth 1998; 10: 539–45.
57. Sharrock NE, Beksac B, Flynn E, Go G, Della Valle AG. Hypotensive epidural anaesthesia in patients with preoperative renal dysfunction undergoing total hip replacement. Br J Anaesth 2006; 96: 207–12.
58. Nguyen NT, Wolfe BM. The physiologic effects of pneumoperitoneum in the morbidly obese. Ann Surg 2005; 241: 219–26.
59. Pastor CM, Morel DR, Clergue F, Mentha G, Morel P. Effects of abdominal Co2 insufflation on renal and hepatic blood flows during acute hemorrhage in anesthetized pigs. Crit Care Med 2001; 29: 1017–22.
60. Nakache R, Szold A, Merhav H, Klausner JM. Kidney graft loss after laparoscopic live donor nephrectomy. Transplant Proc 2000; 32: 683.
61. Troppmann C, McBride MA, Baker TJ, Perez RV. Laparoscopic live donor nephrectomy: a risk factor for delayed function and rejection in pediatric kidney recipients? A UNOS analysis. Am J Transplant 2005; 5: 175–82.
62. Derweesh IH, Goldfarb DA, Abreu SC, et al. Laparoscopic live donor nephrectomy has equivalent early and late renal function outcomes compared with open donor nephrectomy. Urology 2005; 65: 862–6.
63. Wheeler DC. Does lipid-lowering therapy slow progression of chronic kidney disease? Am J Kidney Dis 2004; 44: 917–20.
64. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.
65. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560–72.
66. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52.
67. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547–53.
68. Pool JL. Direct renin inhibition: focus on aliskiren. J Manag Care Pharm 2007; 13: 21–33.
69. Charlson ME, MacKenzie CR, Gold JP, et al. Preoperative characteristics predicting intraoperative hypotension and hypertension among hypertensives and diabetics undergoing noncardiac surgery. Ann Surg 1990; 212: 66–81.
70. Comfere T, Sprung J, Kumar MM, et al. Angiotensin system inhibitors in a general surgical population. Anesth Analg 2005; 100: 636–44.
71. Mehta RL, Pascual MT, Soroko S, Chertow GM. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002; 288: 2547–53.
72. Uchino S, Doig GS, Bellomo R, et al. Diuretics and mortality in acute renal failure. Crit Care Med 2004; 32: 1669–77.
73. Aravindan N, Shaw A. Effect of furosemide infusion on renal hemodynamics and angiogenesis gene expression in acute renal ischemia/reperfusion. Ren Fail 2006; 28: 25–35.
74. Cantarovich F, Rangoonwala B, Lorenz H, Verho M, Esnault VL. High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Am J Kidney Dis 2004; 44: 402–9.
75. Bagshaw SM, Delaney A, Haase M, Ghali WA, Bellomo R. Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Crit Care Resusc 2007; 9: 60–8.
76. Jones D, Bellomo R. Renal-dose dopamine: from hypothesis to paradigm to dogma to myth and, finally, superstition? J Intensive Care Med 2005; 20: 199–211.
77. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005; 142: 510–24.
78. Landoni G, Biondi-Zoccai GG, Tumlin JA, et al. Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Am J Kidney Dis 2007; 49: 56–68.
79. Morelli A, Ricci Z, Bellomo R, et al. Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. Crit Care Med 2005; 33: 2451–6.
80. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. JAMA 2006; 295: 2765–79.
81. Masuda M, Yamada T, Mine T, et al. Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure. Am J Cardiol 2007; 100: 781–6.
82. Pannu N, Tonelli M. Strategies to reduce the risk of contrast nephropathy: an evidence-based approach. Curr Opin Nephrol Hypertens 2006; 15: 285–90.
83. Conesa EL, Valero F, Nadal JC, et al. N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol Regul Integr Comp Physiol 2001; 281: R730–7.
84. Nitescu N, Ricksten SE, Marcussen N, et al. N-acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia-reperfusion. Nephrol Dial Transplant 2006; 21: 1240–7.
85. Macedo E, Abdulkader R, Castro I, et al. Lack of protection of N-acetylcysteine (NAC) in acute renal failure related to elective aortic aneurysm repair: a randomized controlled trial. Nephrol Dial Transplant 2006; 21: 1863–9.
86. Burns KE, Chu MW, Novick RJ, et al. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing CABG surgery: a randomized controlled trial. JAMA 2005; 294: 342–50.
87. Sward K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med 2004; 32: 1310–15.
88. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997; 336: 828–34.
89. Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 2000; 36: 767–74.
90. Mentzer RM, Oz MC, Sladen RN, et al. Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. J Am Coll Cardiol 2007; 49: 716–26.
91. Lee HT, Kim M, Jan M, Emala CW. Anti-inflammatory and antinecrotic effects of the volatile anesthetic sevoflurane in kidney proximal tubule cells. Am J Physiol Renal Physiol 2006; 291: F67–78.
92. Johnson DW, Pat B, Vesey DA, et al. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006; 69: 1806–13.
93. Park J, Gage BF, Vijayan A. Use of EPO in critically ill patients with acute renal failure requiring renal replacement therapy. Am J Kidney Dis 2005; 46: 791–8.
94. Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 2006; 86: 901–40.
95. Morigi M, Imberti B, Zoja C, et al. Mesenchymal stem cells are renotropic, helping to repair the kidney and improve function in acute renal failure. J Am Soc Nephrol 2004; 15: 1794–804.
96. Togel F, Hu Z, Weiss K, et al. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289: F31–42.